REG - Competition and Mkts - Merger Update: CVS/The Vet

CVSAnnouncement

25/05/2022 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220525:nRSY6589Ma&default-theme=true

RNS Number : 6589M  Competition and Markets Authority  25 May 2022

CMA invites comments on veterinary industry merger remedy:

 

The Competition and Markets Authority (CMA) has opened a consultation on
undertakings proposed by CVS Group plc to address competition concerns over
its acquisition of Quality Pet Care Ltd ) trading as The Vet).

 

On 18 February 2022, the CMA announced that it would refer the acquisition for
an in-depth investigation unless CVS offered acceptable undertakings to
address the CMA's concerns.

 

To address the CMA's concerns, CVS has offered to divest the entire The Vet
business.

 

On 4 March 2022, the CMA announced that it would look in detail at these
undertakings. The CMA has until 1 July 2022 to consider whether to accept the
undertakings, or a modified version of them. As part of this process, the CMA
is now consulting publicly on whether the proposals are sufficient to address
the CMA's competition concerns.

 

Before reaching a final decision, the CMA is therefore inviting interested
parties to make their views known. The deadline for responses is Monday 13
June 2022.

 

The consultation on the undertakings and all other information relating to
this merger investigation can be found on the case page at CVS / Quality Pet
Care merger inquiry - GOV.UK (www.gov.uk)
(https://www.gov.uk/cma-cases/cvs-slash-quality-pet-care-merger-inquiry) .

 

In the event of media enquiries please contact press@cma.gov.uk
(mailto:press@cma.gov.uk)   or 020 3738 6460.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MERBUGDUCSDDGDS